REG - Creo Medical Group - FY25 Trading Update

Creo MedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260120:nRST5118Pa&default-theme=true

RNS Number : 5118P  Creo Medical Group PLC  20 January 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

FY25 Trading Update

 

A year of strong financial and operational delivery

50% revenue growth and 20% reduction in underlying operating costs

Continued clinical adoption by new users and increased utilisation of Core
Products

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, provides a trading update for the year ended 31 December 2025
(FY25). All financials below relate to continuing operations.

 

Financial highlights

·    50% revenue growth to £6.0m (FY24: £4.0m), in-line with market
expectations and management guidance, and reflects H2'25 revenue increasing by
58% versus the respective prior period (H2'24: £2.4m) at £3.8m.

·    20% reduction in underlying operating costs to £18.4m (FY24:
£23.8m) reflecting the full impact of actions taken in FY24 and continued
cost control in FY25.

·    Underlying operating loss reduced by more than 40% to £13.3m (FY24:
£22.3m).

·    Cash and cash equivalents of £12.4m at year end (30 June 2025:
£20.5m; 31 December 2024: £8.7m).

 

Operational overview

Creo delivered a strong trading performance in 2025. Revenues were up 50%
supported by continued clinical adoption of Creo's products by new users and
increased demand from existing users as utilisation increased.

 

The Company's core product portfolio, with a growing range of clinical
applications and proven benefits for patients and healthcare practitioners, is
gaining commercial momentum. In particular:

 

Resection:

·    Speedboat® Notch continues to see increased use in advanced
procedures, including upper GI per-oral endoscopic myotomies (POEMs), which
have favourable reimbursement in major markets. There was also increased use
in GI resection procedures, which are expected to benefit from reimbursement
codes in the USA from 2027.

·    Following regulatory clearance and its commercial launch in the US,
UK and EU during the year, the reception of Creo's SpydrBlade™ Flex device
has been encouraging.

 

Ablation

·    MicroBlate™ Flex continued to be employed in multiple studies to
treat lung tumours, with commercial sales from the initial sites now coming
through.

·    A limited market release of MicroBlate™ Fine has taken place in key
research sites in Europe, APAC and the USA, where clinical data will be
collected for the treatment of lesions in the pancreas and liver.

 

There is growing recognition amongst leading clinicians of the benefits of
Creo's innovative products. This is reflected in a growing body of papers,
abstracts and case studies. A selection of these can be accessed through
Creo's Clinical Resources bibliography at:

https://www.creomedical.com/en/investors/creo-medical-clinical-resources-bibliography
(https://www.creomedical.com/en/investors/creo-medical-clinical-resources-bibliography)

 

Outlook

The outlook for FY26 and beyond is positive. The Board is confident in the
Group meeting its expectations for FY26, and with continued sequential growth
period-on-period, improved operational efficiency and financial discipline,
the Company is well positioned on its path to deliver self-sustaining
cashflows and increased value to shareholders.

 

Notice of Results

Creo will announce full year results in April 2026. A further announcement
confirming a date for publication of the results will be issued in due course.

 

Kevin Crofton, Chair, commented:

"The second half of FY25 represents two more consecutive quarters of
consistent delivery against management expectations. We continue to be focused
on achieving high revenue growth, improved operational efficiency and
continued cost control to become cash positive. Strategically, our products
are well positioned in growing attractive markets creating significant
potential for shareholder returns."

 

Craig Guliford, CEO, commented:

"I am proud of our performance in FY25. We have achieved substantial growth in
revenues supported by increased adoption of our core products and growing
demand. In addition, we continued to strengthen our product portfolio with the
introduction of new products and progress in clinical studies that support new
clinical applications in key markets. The benefits of our innovative products
have growing recognition from key opinion leading worldwide. Together, this
creates confidence and optimism for the future potential of Creo."

 

 

For further information please contact:

 

 Creo Medical Group plc                                                      www.creomedical.com
                                                                             (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                           Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Broker and Financial Adviser)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Sher Shah

 Walbrook PR Ltd                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings      Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFZGMMMLFGVZZ



            Copyright 2019 Regulatory News Service, all rights reserved